AstraZeneca published a New Scientist article by Susan Galbraith detailing the science behind a new approach to attack cancer from multiple angles, including antibody drug conjugates, radioconjugates, bispecifics, and immuno-oncology approaches.
Public source
Publisher name
Public post
Cancer is extraordinarily complex, which is why we're exploring ways to attack it from multiple angles. At AstraZeneca, we're advancing a diverse range of scientific app…
Company
AstraZeneca
- Industry
- Pharmaceutical Manufacturing
- Location
- Cambridge, GB
- Company size
- 10,001+ employees
About AstraZeneca
We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com. Community Guidelines: bit.ly/2MgAcio
See moreLatest activity
Latest activity from AstraZeneca
141 signals
Presence & Recognition
AstraZeneca leaders share their vision for how continued scientific progress could transform what is possible by 2040 as they head into WCLC 2026
Presence & Recognition
AstraZeneca is reflecting on the future of lung cancer care ahead of WCLC 2026.
Research & Knowledge
AstraZeneca and partner Amgen announced positive high-level Phase III results from the DeLLphi-305 trial in extensive-stage small cell lung cancer.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
GSK
GSK published a new Custom Content article from The Wall Street Journal by Hesham A. Abdullah, MD, MSc and Chris Sheldon, PhD, sharing their approach to oncology business development.
Research & Knowledge
Pfizer
Pfizer published a newly published preclinical paper showcasing the potential mechanistic rationale for combining ADCs with IO for treating cancer.
Research & Knowledge
MSD in the UK
MSD in the UK published the report It’s About Time: Accelerating the Cancer Patient Pathway highlighting practical examples from Cancer Alliances supporting the National Cancer Plan ambitions.
Research & Knowledge
Orion Pharma
Orion Pharma featured Anu Moilanen and Olli Törmäkangas on a molecule that became a treatment for people living with prostate cancer.
Research & Knowledge
Jazz Pharmaceuticals